Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-92

Old report:

"Despite significant reduction in the pre-specified endpoint of cardiac death, there was no reduction in recurrent non-fatal decompensated heart failure events, which was the trial’s primary endpoint".

New report:

"Patients who received rexlemestrocel-L had a 68% reduction in the rate of recurrent hospitalizations from non-fatal heart attacks or strokes compared with controls, with a hospitalization rate of 1.90 per 100 patient years of follow-up in the rexlemestrocel-L arm versus 5.95 per 100 patient-years of follow-up in the control arm (p=0.0002)".

Happy to be corrected but decompensated heart events can include things like difficulty breathing and other aspects of extreme discomfort. Jeez, looking at these results MSB really did mess up on the primary endpoint. Such a shame they did not pick a more cardiac specific primary endpoint.

These results are different and bode very well for a collaboration and better for FDA in my modest opinion and knowledge of cardiac medicine.